Positive study results for Galectin By: MarketMinute.com Stock News January 07, 2015 at 13:18 PM EST Galectin Therapeutics Inc. (Nasdaq: GALT) reported positive results for a Phase 1 trial of GR-MD-02 on fibrosis lifting the stock price 74 cents to close at $3.97. Related Stocks: Galectin Therapeutic